CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
多发性骨髓瘤中的 CAR-T 细胞治疗：我们现在在哪里，将走向何方？
英文原题：CAR T cell therapy in multiple myeloma, where are we now and where are we heading for?
查看英文原题
CAR T cell therapy in multiple myeloma, where are we now and where are we heading for?
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
近年来，嵌合抗原受体（CAR）T细胞的问世革新了复发/难治性多发性骨髓瘤（RRMM）的治疗。目前，美国和欧盟已批准两种CAR-T 细胞产品——伊德卡博塔基（idecabtagene vicleucel）和西达基奥仑赛（ciltacabtagene autoleucel），用于既往接受过三线治疗的患者；既往治疗需包括蛋白酶体抑制剂、免疫调节药物和抗CD38抗体。此外，这两种药物用于更早治疗线的关键III期试验近期也已发表。尽管CAR-T 细胞在RRMM中实现了前所未有的深度和持久缓解，但其最佳使用方式及在多发性骨髓瘤中的应用定位仍存在不确定性。本综述讨论已获批CAR-T 产品的现有数据、尚未满足的临床需求，以及优化这一有前景治疗方法应用的持续进展。
展开英文摘要原文
The introduction of chimeric antigen receptor (CAR) T cells revolutionized treatment of relapsed and refractory multiple myeloma (RRMM) in recent years. Currently, two CAR T cell products-idecabtagene vicleucel and ciltacabtagene autoleucel-are approved in the United States and the European Union to treat patients with three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.
Moreover, seminal phase III trials of both agents in earlier lines of therapy have been published recently. Despite unprecedented rates of deep and lasting remissions in RRMM, there are still areas of uncertainty regarding the optimal use and distribution of CAR T cells in multiple myeloma. In the current review, we discuss the available data on approved CAR T cell products as well as unmet clinical needs and ongoing developments to optimize usage of this promising treatment modality in multiple myeloma.
论文信息
- 作者
- Fischer L、Grieb N、Platzbecker U、Vucinic V、Merz M
- 单位
- Department of Hematology, Cellular Therapy, Hemostaseology and Infectiology, University Hospital of Leipzig, Leipzig, Germany.Germany
- 文献类型
- 综述
- 期刊
- European journal of haematology2024 Jan
- 原文标识
- PubMed 37547971 · DOI 10.1111/ejh.14051